Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885858 | 0.88 | ADRB1 (0.42) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL17857367 | 0.88 | ADRB1 (0.42) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL23729048 | 0.83 | ALDH1A1 (0.39) | ADRB1ALDH1A1HPGDSMN1; SMN2MGLL | |
| SCHEMBL20693382 | 0.81 | ADRB1 (0.40) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL16967089 | 0.81 | ADRB1 (0.46) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL16307945 | 0.80 | ALDH1A1 (0.47) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL18966917 | 0.78 | MEN1 (0.45) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL20693377 | 0.77 | ALDH1A1 (0.42) | ADRB1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL22781105 | 0.77 | ALDH1A1 (0.44) | ADRB1ALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL20049846 | 0.76 | ADRB1 (0.42) | ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3995524-A1 | DUAL CURE SYSTEM FOR THE CHEMICAL FIXATION OF AN ANCHORING AGENT IN A DRILLED HOLE | Hilti Aktiengesellschaft (LI) | 2022-05-11 | — | — | EP | disclosed |
| EP-3995525-A1 | MONOMER WITH TWO POLYMERISABLE GROUPS (FOR ROMP AND FOR RADICAL POLYMERISATION) AND ITS USE | Hilti Aktiengesellschaft (LI) | 2022-05-11 | — | — | EP | disclosed |
| US-20210332011-A1 | TOTAL SYNTHESIS OF PROSTAGLANDIN J NATURAL PRODUCTS BY TEREORETENTIVE METATHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | disclosed |
| US-10857530-B2 | Olefin metathesis catalysts | UMICORE AG & CO. KG (DE) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857530-B2 | Olefin metathesis catalysts | ZDHHC7, ZDHHC2, OSBP | ADRB1 4007/4885ALDH1A1 1629/4885HPGD 1836/4885 |
| US-20210332011-A1 | TOTAL SYNTHESIS OF PROSTAGLANDIN J NATURAL PRODUCTS BY TEREORETENTIVE METATHESIS | PTGES, PTGES2, PTGIS | ADRB1 716/4885ALDH1A1 3137/4885HPGD 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.